Free Articles

In the News

The Burrill Report interviews Greg Scott on WuXi/CRL breakup and China's hot IPOs

>>Burrill podcast...

Greg Scott joined Foley's Eye on China webinar on life science innovation
>>Foley webinar...

Site Search

>> Advanced Search

Free Newsletter

>> Preview...

Free Content

Week in Review

In My Opinion

Free Articles

Education Center

Interfax-BW Releases

SFDA What's New

Subscriber Content

News & Analysis

Featured Companies

Industry Insights

Deals & Financings

Trials & Approvals

Stem Cells

CRO/CMO Services

Gov't & Regulatory

Legal & IP Issues

Stock Watch

Week in Review

Archived Articles

You are here: Home » Free Articles

These articles are provided free to all readers. Other free articles are available in Week in Review, In My Opinion, and Education Center. To have access to all of our articles, click here...

Recent Articles

The Week in Review: Golden Meditech Raises $40 Million Aug 28, 2010: Golden Meditech raised $40 million in private equity for its autologous blood recovery medical device JV; Boehringer Ingelheim held the formal opening of an R&D center in Shanghai; 3SBio in-licensed the China rights to an anti-rejection drug from Isotechnika; China PharmaHub will distribute radioactive glass spheres in China to treat liver cancer; Xiamen Innovax Biotech’s vaccine for hepatitis B was effective in a Phase III trial; Lotus Pharma began a Phase I trial of R-Bambuterol®, an asthma treatment; and Aoxing Pharma received SFDA approval to begin a clinical trial of a treatment for opioid addiction. More details….

Stock Symbols: (HKEX: 801) (NSDQ: SSRX) (TSX: ISA) (OTCBB: WRLC) (OTCBB: LTUS) (NYSE Amex: AXN)

The Week in Review: Upping the Stakes Aug 21, 2010: Tongjitang Chinese Medicines Co. is still considering the $4.50 per ADS buyout offer from its Chairman/CEO and Fosun Industrial; GSK will purchase an additional 9% of its vaccine JV with Neptunus Interlong; Accord Pharma will pay $4 million for the rest of Sinopharm Traditional Chinese Medicine; China approved the merger between Novartis and eye-products company Alcon with conditions; Jiangbo Pharma received manufacturing approval for a hypertension drug; Sinovac Biotech’s revenues are lower now that the fear of flu is abating; and Sinopharm Group will locate its antibiotic manufacturing center in Datong City, Shanxi province. More details….

Stock Symbol: (NYSE: TCM) (NYSE: GSK) (SHEX: 000028) (NYSE: NVS) (NYSE: ALC) (NSDQ: JGBO) (NSDQ: SVA) (HKEX: 01099)

The Week in Review: China to Unveil More Support for Biopharma Aug 14, 2010: China’s 12th Five Year Plan (2011-2015) for biopharma may have over 10 billion RMB ($1.5 billion) in development support for new drugs; the total 2009 output value of China’s pharmaceutical sector topped 1 trillion RMB ($148 billion) in 2009; WuXi PharmaTech will spend $100 million to build a new R&D facility in Wuhan; Kanghui Holdings priced its IPO at $10.25 per ADS and moved higher; Mindray Medical reported higher numbers for Q2 but lowered guidance; QIAGEN expects its China revenues to double this year; Tianjin Tasly Pharma reported positive Phase II results from a US trial of its TCM treatment for angina; Sinobiopharma partnered with Jiangsu Lianhuan Pharma to develop a hypertension drug; and Simcere Pharma received SFDA approval to market a drug that treats cancer-induced nausea. More details….

Stock Symbols: (NYSE: WX) (NYSE: KH) (NYSE: MR) (NSDQ: QGEN) (SHEX: 600535) (OTCBB: SNBP) (NYSE: SCR)

The Week in Review: China Orthopedic Device Maker Plans NYSE Debut Aug 7, 2010: China Kanghui Holdings reported increased Q2 results and detailed plans for its $69 million IPO on the NYSE; Sangon Biotech, a Shanghai life science research service company, received $10 million in VC from Qiming Ventures; the Scientific American devoted a special section to China’s biopharma innovation; the SFDA will soon complete a national network to monitor all 307 drugs on the Essential Drug List; and recently spurned merger partner WuXi PharmaTech increased its guidance for 2010 while suitor Charles River trimmed its 2010 outlook. More details….

Stock Symbols: (NYSE: WX) (NYSE: CRL)

The Week in Review: Charles River Cancels Merger with WuXi Jul 31, 2010: The proposed merger between Charles River Labs and WuXi AppTec was cancelled because Charles River’s investors felt the company overpaid; Dr. Ge Li, Chairman and CEO of WuXi blamed “short-term financial” worries for the merger’s demise; we argued that Charles River may be passing up a one-time opportunity to establish near-complete global CRO dominance; China Kanghui Holdings, a medical-device company, filed for an IPO on the NYSE; Kangmei Pharma will purchase two TCM companies in Sichuan; Radient Pharma announced a new plan to sell its China subsidiary, Jade Pharma; Affymetrix is developing a genotyping array specifically for Chinese populations; Merck signed a letter of intent with Sinopharm to market its HPV vaccine; and China has signed an intellectual property agreement with Taiwan. More details….

Stock Symbols: (NYSE: CRL) (NYSE: WX) (SHEX: 600518) (AMEX: RPC) (NSDQ: AFFX) (NYSE: MRK) (SHEX: 600511)

Charles River’s Decision Shows Misunderstanding of Pharma’s Future Jul 31, 2010: This week's announcement that some of Charles River Laboratories’ investors blocked the deal to acquire WuXi AppTec is remarkable in several aspects. Most importantly, Charles River is passing up a one-time opportunity to establish near-complete global dominance in its industry. The deal significantly undervalued WuXi because it ignored the strategic value of WuXi itself, which is the dominant player in the world's most important emerging market. More details...

Stock Symbols: (NYSE: WX) (NYSE: CRL)

The Week in Review: China Pharma IPOs Raise $5.4 Billion in 12 Months Jul 24, 2010: China life science IPOs raised $5.4 billion in the last 12 months, led by the $1.3 billion IPO of Sinopharm Group; China’s central government spent $11.8 billion on healthcare reform in the first half of 2010; CCBI Healthcare Fund made an investment in Shanghai Kindly Enterprise Development Group; Lijun International Pharmaceutical set up a Joint Venture with Tonghua Dongbao Pharma in Jilin Province; BioHorizons has asked the SFDA for approval of its dental implant products; BMP Sunstone rose more than 10% on Monday on rumors it would be acquired; Lee's Pharma will be the exclusive China distributor for Remodulin, a United Therapeutics product; Beike Biotechnology opened a rehabilitation center in Romania; Novartis reported the SFDA has approved China use of Rasilez®, a treatment for high blood pressure; and Bayer Schering AG and The People’s Liberation Army General Hospital (301 Hospital) of Beijing have begun a research collaboration to study women’s health. More details....

Stock Symbols: (HKEX: 0939) (HKEX: 02005) (SHEX: 600867) (NSDQ: BJGP) (GEM: 8221) (NSDQ: UTHR) (NYSE: NVS)

The Week in Review: Charles River/Wuxi PharmaTech Back in the News Jul 17, 2010: Charles River Labs and WuXi PharmaTech (药明康德) expect their merger to produce up to $100 million in increased revenues by cross-selling and $20 million in cost savings; WuXi PharmaTech reported upbeat Q2 financial results; Fosun Pharma and Grupo Chemo of Spain will invest $73.8 million to develop four monoclonal antibody drugs; China PharmaHub will seek foreign biotech and medical device technology for acquisition by Sichuan companies; Merck Sharp & Dohme started construction of a $162 million drug packaging plant in Hangzhou; IBM collaborated with Peking University People's Hospital to build an evidence-based patient record system; Dehaier Medical Systems acquired a line of emergency ventilators from Beijing Qiumanshi Technology Co.; NeoStem received a grant to study a topically applied stem cell wound healing product; and Shandong Lukang Pharma expects a first half profit increase of 700%. More details....

Stock Symbols: (NYSE: CRL) (NYSE: WX) (SHEX: 600196) (OTCBB: WRLC) (NYSE: MRK) (NYSE: IBM) (NSDQ: DHRM) (NYSE Amex: NBS) (SHEX: 600789)

The Week in Review: More CRO Consolidation Jul 10, 2010: Venturepharm Lab signed a letter of intent with an unnamed “large multinational healthcare company” to form a clinical CRO joint venture; the largest 100 China pharmas are increasing their share of China drug market; China Animal Healthcare raised $45 million to expand its vaccine business; Artepharm Global announced a $10 million anti-malaria project in Africa; HEGLN (Dalian) Pharma paid $2 million to acquire a non-invasive urologic diagnostic technology; and Swedish Orphan Biovitrum partnered with Tonghua Dongbao Pharma (see story) to market each other’s products. More details…

Stock Symbols: (SI: CAHC) (OTCBB: ARGC) (STO: SOBI) (SHEX: 600867)

The Week in Review: ChinaBio® Partnering Forum Jul 3, 2010: Representatives of 337 companies from 23 countries attended the successful Second Annual ChinaBio® Partnering Forum 2010 in Suzhou, China; Fountain Medical Development and ICON plc will jointly operate a central lab facility in Tianjin; Zhejiang Huahai Pharma will spin off its US generic drug business; China PharmaHub set up a JV built around new technology for humanizing antibodies; NeoStem raised $5 million in a private placement; ULURU out-licensed the China rights for its wound healing product to Jiangxi Aiqilin Pharma; and China Nuokang Bio-Pharmaceutical struck a deal to register and distribute Dianatal® Obstetric Gel in China. More details...

Stock Symbols: (NSDQ: ICLR) (SHEX: 600521) (NYSE Amex: NBS) (NYSE Alternext: ULU) (NSDQ: NKBP)